AtheroGenics to Present at Tucker Anthony Sutro Health Care Conference

Apr 02, 2001, 01:00 ET from AtheroGenics, Inc.

    ATLANTA, April 2 /PRNewswire/ -- AtheroGenics, Inc. (Nasdaq: AGIX), an
 emerging pharmaceutical company focused on the treatment of chronic
 inflammatory diseases, today announced that it will present at the Tucker
 Anthony Sutro Health Care Investor Conference on Wednesday, April 4, 2001, at
 2:15 p.m. PDT.  The conference will be held at the Ritz-Carlton Hotel in
 Laguna Niguel, CA.
     AtheroGenics, Inc. is focused on the discovery, development and
 commercialization of novel drugs for the treatment of chronic inflammatory
 diseases such as heart disease (atherosclerosis), rheumatoid arthritis and
 asthma.  The company designed its lead product candidate, AGI-1067, to benefit
 patients with coronary artery disease, which is atherosclerosis of the blood
 vessels of the heart.  AtheroGenics has completed dosing of AGI-1067 in a 300-
 patient Phase II clinical study for the treatment of post-angioplasty
 restenosis, with study results anticipated in the second quarter of 2001.
 AtheroGenics' second product candidate, AGIX-4207, is a novel, orally-
 administered drug for the treatment of rheumatoid arthritis.  The company
 recently began enrollment in a Phase I clinical trial to assess the safety and
 tolerability of AGIX-4207.  For more information, please visit
 www.atherogenics.com .
     This press release may contain forward-looking statements made pursuant to
 the safe harbor provisions of the Private Securities Litigation Reform Act of
 1995.  Such statements are subject to certain factors, risks and uncertainties
 that may cause actual results, events and performance to differ materially
 from those referred to in such statements.  These risks include statements
 which address operating performance, events or developments that we expect or
 anticipate will occur in the future, the development of our product
 candidates, and other such risks that could cause actual results to differ
 materially.  These risks are discussed in AtheroGenics' SEC filings, including
 the company's registration statement on Form S-1, Registration No. 333-31140,
 filed with the Securities and Exchange Commission, and including but not
 limited to the risks discussed in AtheroGenics' Form 10-K report for fiscal
 2000, both of which are incorporated by reference into this press release.
 
 

SOURCE AtheroGenics, Inc.
    ATLANTA, April 2 /PRNewswire/ -- AtheroGenics, Inc. (Nasdaq: AGIX), an
 emerging pharmaceutical company focused on the treatment of chronic
 inflammatory diseases, today announced that it will present at the Tucker
 Anthony Sutro Health Care Investor Conference on Wednesday, April 4, 2001, at
 2:15 p.m. PDT.  The conference will be held at the Ritz-Carlton Hotel in
 Laguna Niguel, CA.
     AtheroGenics, Inc. is focused on the discovery, development and
 commercialization of novel drugs for the treatment of chronic inflammatory
 diseases such as heart disease (atherosclerosis), rheumatoid arthritis and
 asthma.  The company designed its lead product candidate, AGI-1067, to benefit
 patients with coronary artery disease, which is atherosclerosis of the blood
 vessels of the heart.  AtheroGenics has completed dosing of AGI-1067 in a 300-
 patient Phase II clinical study for the treatment of post-angioplasty
 restenosis, with study results anticipated in the second quarter of 2001.
 AtheroGenics' second product candidate, AGIX-4207, is a novel, orally-
 administered drug for the treatment of rheumatoid arthritis.  The company
 recently began enrollment in a Phase I clinical trial to assess the safety and
 tolerability of AGIX-4207.  For more information, please visit
 www.atherogenics.com .
     This press release may contain forward-looking statements made pursuant to
 the safe harbor provisions of the Private Securities Litigation Reform Act of
 1995.  Such statements are subject to certain factors, risks and uncertainties
 that may cause actual results, events and performance to differ materially
 from those referred to in such statements.  These risks include statements
 which address operating performance, events or developments that we expect or
 anticipate will occur in the future, the development of our product
 candidates, and other such risks that could cause actual results to differ
 materially.  These risks are discussed in AtheroGenics' SEC filings, including
 the company's registration statement on Form S-1, Registration No. 333-31140,
 filed with the Securities and Exchange Commission, and including but not
 limited to the risks discussed in AtheroGenics' Form 10-K report for fiscal
 2000, both of which are incorporated by reference into this press release.
 
 SOURCE  AtheroGenics, Inc.